Stock Report

Download full stock data and analysis for free Last Updated: 07-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Y-mAbs Therapeutics (YMAB) Key Ratios

Stock Card factsheet share-fund-plan-icon

$8.61

$0.00 (0.00%)

As on 16-Sep-2025 09:30EDT

Market cap

info icon

$391 Mln

Revenue (TTM)

info icon

$85 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

4.5

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -6.60 -14.36 -1.34 28.92 --
EBIT -- -- 23.61 22.55 12.68
Net Profit 37.66 64.98 9.71 22.48 12.53
EPS 37.96 65.98 11.92 22.58 12.87
Book Value -- -- -11.43 -20.83 -16.34
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-24Dec-23
EBIT-Margin info -70.37-223.98-24.73-35.58-30.27
Net Margin info ---309.14-26.03----
Return on equity info -39.24-47.09-24.76-30.74-20.39
Return on Capital info -38.61-46.20---30.39-20.08
Return on Assets info -31.41-39.08-13.56-23.95-15.91
Debt to Equity (x) info ----0.000.010.01

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
--
-30.39
-20.08
-65.37
-38.39
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-24.76

Higher than Peers by 15.57

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
-24.76
-30.74
-20.39
-66.59
-39.41
Peer Median
-40.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-13.56

Higher than Peers by 17.68

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
-13.56
-23.95
-15.91
-54.38
-32.68
Peer Median
-31.24
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-24.73

Higher than Peers by 57.86

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
-24.73
-35.58
-30.27
-145.27
-330.78
Peer Median
-82.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-26.03

Higher than Peers by 65.27

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
-26.03
-33.83
-25.26
-147.59
-59.28
Peer Median
-91.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

Lower than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
0.00
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

-1.34

Lower than Peers by 55.38

Year on year growth in net sales

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
-1.34
0.03
0.30
0.87
0.68
Peer Median
54.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

23.61

Higher than Peers by 24.63

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
23.61
-21.54
72.92
17.86
3.75
Peer Median
-1.02
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

9.71

Higher than Peers by 17.24

Year on year growth in profit after tax

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
9.71
-38.45
77.76
-70.96
52.78
Peer Median
-7.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

11.92

Lower than Peers by 2.31

Year on year growth in earnings per share

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
11.92
-0.35
0.77
-0.67
0.52
Peer Median
14.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-10.85

Lower than Peers by 0.72

Year on year growth in book value per share

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
-10.85
--
--
--
--
Peer Median
-10.13
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
--
0.01
0.01
0.02
0.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.01

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
0.01
0.01
0.02
0.02
0.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

4.00

Lower than Peers by 1.81

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
4.00
4.16
5.52
4.61
7.26
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.58

Lower than Peers by 2.12

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
3.58
3.85
5.27
4.38
7.06
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
--
--
--
-125.25
-62.33
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

18.43

Lower than Peers by 0.58

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
18.43
22.45
26.47
19.20
22.10
Peer Median
19.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.52

Higher than Peers by 0.46

Sales / Average Total Assets

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
0.52
0.71
0.63
0.37
0.20
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
--
87.77
75.33
56.64
44.55
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
--
147.04
188.24
294.78
342.29
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
--
152.34
323.71
669.17
1,665.27
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
--
82.47
-60.14
-317.75
-1,278.43
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
--
-11.84
-13.89
-2.26
-12.54
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

4.47

Lower than Peers by 0.86

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
4.47
3.82
2.95
2.00
3.92
Peer Median
5.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-0.43

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
-0.43
-9.29
-8.84
-1.21
-4.61
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

391

Higher than Peers by 250

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Y-mAbs Therapeutics (YMAB)
391
--
--
--
--
Peer Median
142
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...